Matinas BioPharma Holdings, Inc.'s latest marketcap:
As of 07/29/2025, Matinas BioPharma Holdings, Inc.'s market capitalization has reached $4.65 M. According to our data, Matinas BioPharma Holdings, Inc. is the 44086th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 4.65 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -20,083,000 |
| Shares Out | 5.09 M |
| EPS (ttm) | -3.98 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/13/2025 |
Matinas BioPharma Holdings, Inc.'s yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/29/2025 | $4.65 M | 80.77% | 44086 |
| 12/31/2024 | $2.6 M | -94.47% | n/a |
| 12/29/2023 | $47 M | -56.64% | n/a |
| 12/30/2022 | $108.4 M | -50.37% | n/a |
| 12/31/2021 | $218.4 M | -19.41% | n/a |
| 12/31/2020 | $271 M | -26.64% | n/a |
| 12/31/2019 | $369.4 M | 452.17% | n/a |
| 12/31/2018 | $66.9 M | -37.94% | n/a |
| 12/29/2017 | $107.8 M | n/a |
Company Profile
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.
The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Frequently Asked Questions
-
What is Matinas BioPharma Holdings, Inc.'s (MTNB) current market cap?As of 07/29/2025, Matinas BioPharma Holdings, Inc. (including the parent company, if applicable) has an estimated market capitalization of $4.65 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Matinas BioPharma Holdings, Inc. (MTNB) rank globally by market cap?Matinas BioPharma Holdings, Inc. global market capitalization ranking is approximately 44086 as of 07/29/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.